News und Analysen
EQS-News: Evotec publishes Annual Report 2022 and Quarterly Statement for Q1 2023
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
EQS-News: MorphoSys Highlights Potential of Its Mid- to Late-Stage Oncology Pipeline at 2023 ASCO and EHA Annual Meetings
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
EQS-News: RHÖN-KLINIKUM AG looks back on successful Q1 2023
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
Exelixis (EXEL) Q1 2023 Earnings Call Transcript
Image source: The Motley Fool.
Exelixis (NASDAQ: EXEL)Q1 2023 Earnings CallMay 09, 2023, 5:00 p.m. ET
Operator
Source Fool.com
Invitae (NVTA) Q1 2023 Earnings Call Transcript
Image source: The Motley Fool.
Invitae (NYSE: NVTA)Q1 2023 Earnings CallMay 09, 2023, 4:30 p.m. ET
Operator
Source Fool.com
Why Catalent Stock Was in the Red Again Today
Beleaguered healthcare stock Catalent (NYSE: CTLT) took the latest in a series of drubbings on the market Tuesday. This one wasn't as bad as those of previous sessions, although that was surely cold
EQS-News: Just – Evotec Biologics launches tech partnership for biosimilars development and commercial manufacturing
EQS-Adhoc: Just – Evotec Biologics enters strategic biosimilars partnership with Sandoz
The Vanguard Group, Inc.: Horizon Therapeutics plc
Why Catalent Stock Was a Disaster Today
The struggles of contract drugmaker Catalent (NYSE: CTLT) continued on Monday, leading to a big sell-off in the company's stock. Investors were heavily discouraged by their company's latest update
Why Wall Street Took a Hit From These 2 NYSE Stocks
Monday was a relatively quiet day on Wall Street, with most major benchmarks seeing modest losses at midday. With key inflation and other economic data coming in the near future, investors are
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
Should You Buy Novocure Stock Right Now?
Going, going, gone? That could be the question that Novocure (NASDAQ: NVCR) investors are asking these days. Shares of the oncology company plunged 56% in 2021. The stock slid 2% lower last year
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics Plc
EQS-News: SARTORIUS AG: Sartorius announces CFO transition
EQS-News: MorphoSys AG Reports First Quarter 2023 Financial Results
Amarin Plc (AMRN) Q1 2023 Earnings Call Transcript
Image source: The Motley Fool.
Amarin Plc (NASDAQ: AMRN)Q1 2023 Earnings CallMay 03, 2023, 8:00 a.m. ET
Operator
Source Fool.com
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
Almirall: Up to 73% of Atopic Dermatitis Patients Taking Lebrikizumab Had Improved or Cleared Skin on Face or Hands in New Analysis
Almirall S.A. (ALM) today announced results from a new secondary analysis from the Phase 3 clinical development program which showed patients receiving lebrikizumab who were assessed at 16 weeks
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics Plc
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics Plc
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc